- $22.41bn
- $21.91bn
- $606.42m
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Brief: Insmed Inc Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
Insmed falls after lung disease treatment misses sales expectations
Insmed Q1 revenue jumps 230%, net loss narrows
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
HC Wainwright cuts PT on Insmed after skin condition study failure
Insmed discontinues development of skin condition drug after mid-stage study miss (updated)
NASDAQ RESUMED AT 04:30 PM
Insmed discontinues development of skin condition drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:00 PM